De Bruin et al. [43] has recently demonstrated an effective methodology in detecting the glutamic acid-to-lysine mutation at position 17 in AKT1 (AKT1 E17K mutation), a mutation that is of low prevalence among cancer patients, in tissue and plasma samples of advanced cancer patients. Here, AKT1 is linked to cancer.